Alexza Finds New U.S. Marketing Partner For Adasuve In Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant.
You may also be interested in...
Alexza's Last Stand: Hoping For Buyout Or License Of Adasuve
Facing a potential shutdown at the end of April, the California drug-delivery firm hopes either to be purchased by its Spanish partner or find a new licensee of US rights to its inhalable antipsychotic.
EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).
Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.